CLINICAL_TRIALS
trial_result
· 2020-01-18
Clinical Trial Update: A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis [Phase 3]
Summary
Phase 3 trial update for baricitinib in moderate-to-severe atopic dermatitis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2020-01-18